Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3752
Revised: May 22, 2024
Accepted: May 30, 2024
Published online: September 15, 2024
Processing time: 182 Days and 6.4 Hours
With continuous advancements in interventional radiology, considerable progress has been made in transarterial therapies for hepatocellular carcinoma (HCC) in recent years, and an increasing number of research papers on transarterial therapies for HCC have been published. In this editorial, we comment on the article by Ma et al published in the recent issue of the World Journal of Gastro
Core Tip: Articles on transarterial therapies for hepatocellular carcinoma (HCC) were systematically reviewed. The results of this study showed that transarterial therapies combined with systemic therapy strategies are research hotspots in this field, and researchers dedicated to transarterial therapies for HCC should pay attention to these topics in the future.
- Citation: Zhou MT, Zhang P, Mao Q, Wei XQ, Yang L, Zhang XM. Current research status of transarterial therapies for hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(9): 3752-3760
- URL: https://www.wjgnet.com/1948-5204/full/v16/i9/3752.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i9.3752
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver and is the sixth most common cancer and the third leading cause of cancer deaths worldwide[1,2]. Hepatectomy and liver transplantation are radical treatments for early HCC[3]. However, most patients with HCC are already in the middle or advanced stages at the time of diagnosis and have lost the opportunity for surgical treatment. Studies have shown that transarterial therapies, including transarterial chemoembolization (TACE), transarterial embolization (TAE), hepatic artery infusion che
TACE is the standard treatment for Barcelona Clinic Liver Cancer (BCLC) B HCC patients[9]. However, due to the heterogeneity of HCC, improving the efficacy of TACE is a challenge that requires further investigation[10,11]. Studies have confirmed that TACE combined with radiofrequency ablation (RFA) is superior to RFA alone, especially for patients with large-sized HCCs[12,13]. The efficacy of TACE combined with radiation therapy is superior to that of TACE alone[14], especially for advanced HCC patients with vascular invasion[15]. In theory, TACE causes tumor tissue hypoxia, resulting in vascular endothelial growth factor (VEGF) upregulation, which may lead to tumor revascularization and local recurrence. TACE combined with antiangiogenic agents is expected to inhibit the revascularization effect due to the TACE-induced upregulation of VEGF and delay tumor progression or recurrence. However, the results of clinical randomized controlled trials comparing TACE combined with sorafenib and TACE alone are inconsistent, i.e., neither the SPACE nor TACE 2 trials showed any clinical benefit[16,17]; however, the TACTICS trial reported positive results. In the TACTICS trial, the progression-free survival (PFS) of patients in the TACE + sorafenib group (25.2 months) was significantly greater than that of patients in the TACE alone group (13.5 months) (P = 0.006)[18]. The inconsistency of the results of these trials may be related to differences in the study protocols, especially the definition of tumor progression, and differences in the timing of sorafenib administration. In recent years, immunotherapy has shown great potential in the treatment of HCC[19-24]. The combination of TACE and immunotherapy is promising. A number of studies have shown that for patients with unresectable HCC, TACE combined with a tyrosine kinase inhibitor (TKI) plus an immune checkpoint inhibitor (ICI) is more satisfactory than TKI plus an ICI alone or TACE + sorafenib, exhibiting better efficacy and safety[25-38].
TAE, also known as bland embolization, is the injection of an embolic substance into the feeding artery of a HCC via a catheter under X-ray fluoroscopy to achieve a therapeutic effect by inducing lesion ischemia[39]. Due to the lack of chemical toxicity and radiotoxicity, the tumor response is mainly due to the cell death mechanism during hypoxia; therefore, TAE is advantageous for some patients in whom healthy liver parenchyma needs to be retained. Compared with supportive care, TAE provides a survival benefit for patients with unresectable HCC[40].
Currently, the comparison of TAE and TACE is still the focus of studies, but the study results are not consistent. Many studies have shown that there is no significant difference in overall survival (OS) between TAE and conventional TACE (cTACE)[41,42]. There are also some data showing that cTACE is superior to TAE in terms of treatment response[43]. For example, Meyer et al[43] performed a randomized controlled trial to compare the efficacy of TAE and TACE, and the results showed that the end-of-treatment RECIST responses [complete response + partial response] were 13.2% and 32.6% (P = 0.04), respectively; the mRECIST responses were 47.3% and 67.4%, respectively; and the median OS and PFS were 17.3 and 16.3 months (P = 0.74) and 7.2 and 7.5 months (P = 0.59), respectively.
Recently, Gao et al[44] studied the antitumor effect of TAE combined with the kringle 1 domain of human hepatocyte growth factor alpha (HGFK1, an angiogenesis inhibitor) in an in situ rabbit HCC model. The results showed that the expression levels of cluster of differentiation 31 (CD31), CD90, and Ki67 significantly decreased after treatment with TAE and HGFK1 and that both TAE and HGFK1 prolonged the survival of rabbits (P < 0.05)[44].
HAIC involves the direct injection of chemotherapeutic drugs into the feeding artery of HCC through a catheter to increase the local drug concentration in the tumor, thereby increasing the response rate and reducing the systemic toxic side effects of chemotherapeutic drugs. HAIC is a promising method for the treatment of advanced HCC and has become increasingly popular in recent years[45,46].
Studies have shown that HAIC could improve OS and PFS in patients with advanced HCC[47,48]. After surgical resection, adjuvant HAIC-FOLFOX improved disease-free survival (DFS) in HCC patients with microvascular invasion (MVI). In a randomized multicenter trial[49], 315 patients with histologically confirmed MVI-positive HCC were randomly assigned to receive FOLFOX-HAIC adjuvant therapy (the treatment group with 157 patients) or conventional follow-up (the control group with 158 patients), and the results showed that the median DFS in the treatment group was 20.3 months and that in the control group was 10.0 months (P = 0.001); the 1-, 2-, and 3-year OS rates in the treatment group were 93.8%, 86.4%, and 80.4%, respectively, and those in the control group were 92.0%, 86.0%, and 74.9%, respectively.
Currently, the platinum-based HAIC regimen is recommended as the first-line treatment for advanced HCC in Asia (China and Japan). Gourd et al[50] reported that for patients with HCC at a stage suitable for TACE, the efficacy of HAIC in the treatment of advanced HCC may be greater than that of TACE[50,51].
Sorafenib and lenvatinib are internationally recognized first-line treatment drugs for advanced HCC[52-54]. Studies have shown that the outcomes of HAIC combined with targeted therapy are superior to those of TACE[55]. Chen et al[56] performed a network meta-analysis to analyze the difference in efficacy between HAIC combined with sorafenib and TACE combined with sorafenib for the treatment of unresectable HCC, and the results showed that the overall response rate of patients who received sorafenib + FOLFOX-HAIC treatment was significantly greater than that of patients who received other regimens [odds ratio (OR) = 22.18, 95%CI: 10.69-52.56]. There were significant differences between patients who received the sorafenib plus HAIC-oxaliplatin regimen and patients who received other treatment strategies in terms of OS [hazard ratio (HR) = 0.33, 95%CI: 0.25-0.44]. Sorafenib combined with HAIC and oxaliplatin improved OS; rank probability plots showed that there was a 99.9% likelihood of sorafenib plus FOLFOX-HAIC being the most effective treatment, followed by sorafenib plus TACE at a likelihood of 86.6% and sorafenib combined with cisplatin-HAIC at a likelihood of 75.6%; and the incidence of liver injury increased in the sorafenib plus TACE treatment group (OR = 5.93, 95%CI: 2.70-15.41), with no difference in the incidence of other serious adverse events between treatment groups. In addition, published studies have also shown the efficacy and safety of HAIC combined with ICIs and TKIs in the treatment of advanced HCC[57-61].
In summary, HAIC can be used as a standard treatment for advanced HCC, and HAIC combined with targeted therapy and immunotherapy may further improve the survival of patients with advanced HCC.
In TARE, Y90 and holmium-166 (166Ho) are delivered via resin or glass microspheres to the arterialized tumor vasculature to deliver an inhibitory dose to the tumor. The results of an early trial of TARE were not satisfactory. In recent years, with advancements in ablation techniques and personalized dosimetry, substantial progress has been made in TARE, which has played a prominent role in the locoregional treatment of HCC and has been incorporated into the 2022 BCLC algorithm[62].
TARE combined with targeted therapy and immunotherapy has also yielded good results[62-65]. Kaseb et al[63] first conducted a prospective study of Y-90 combined with sorafenib in the treatment of advanced HCC, with 38 patients with advanced/metastatic HCC and 34 patients who first received sorafenib treatment and then Y-90 GM treatment 4 weeks later. The results showed that the combination therapy was well tolerated, the median PFS and OS were 10.4 months (95%CI: 5.8-14.4) and 13.2 months (95%CI: 7.9-18.9), respectively, partial remission was achieved in 12 patients (35.3%), and the condition of 16 patients (47.0%) was stable. Recently, Yeo et al[64] studied the efficacy and safety of TARE combined with immunotherapy in patients with advanced HCC, with 1664 eligible advanced HCC patients. Among them, 142 patients received TARE + immunotherapy treatment, and 1522 patients received immunotherapy alone. The results showed that the median OS of the combination therapy group was significantly higher than that of the immunotherapy alone group (19.8 months vs 9.5 months); in the multivariate analysis, combination therapy was independently associated with reduced mortality. The favorable results for TARE + immunotherapy support the application prospects of TARE.
Systemic chemotherapy is administered through peripheral veins and delivered throughout the body, but the main problems are insufficient drug uptake by targeted tumor tissues and systemic toxicity. The local application of anticancer drugs can produce substantially higher drug concentrations in tumor tissues with less systemic toxicity; various locoregional treatments, including intra-arterial treatments, have become HCC treatment strategies. However, local treatments via the hepatic artery also face various challenges, and the survival benefit is still limited. Therefore, it is necessary to develop drug transporters that can reach targets more effectively or to develop more effective drug delivery methods to improve therapeutic effects[66].
cTACE uses lipiodol-based emulsions combined with an embolizing agent for chemotherapy and embolization via transcatheter delivery to achieve powerful cytotoxic and ischemic effects. The chemotherapeutic drugs emulsified in iodized oil used in cTACE are poorly stable and may lead to systemic adverse effects[67,68]. Zhao et al[67] reported a composite hydrogel, Epi/Etpoil@MC/XG, that can stably distribute Etpoil and Epi and has been successfully applied for the embolization of feeding arteries in a VX2 tumor model. To alleviate the high incidence of systemic adverse reactions associated with cTACE, TACE with drug-eluting beads (DEB-TACE) was developed. DEB-TACE provides more selective and controllable drug delivery through microspheres, which slowly release chemotherapeutic drugs, maintain the action time of chemotherapeutic drugs, and increase the intensity of ischemia[69-71].
The balloon-occluded TACE (B-TACE) technique, which was first reported by Irie et al[72], refers to the use of a microballoon catheter to occlude the tumor feeding artery and then to perfuse the chemotherapeutic drug emulsion and gelatin sponge particles to cause the dense accumulation of chemical emulsions containing iodized oil in target nodules[72]. A preliminary study showed that the treatment effect of B-TACE was superior to that of cTACE[73,74]. In the future, randomized controlled trials with large sample sizes are needed to compare B-TACE with cTACE or DEB-TACE.
In contrast to TACE, which relies on the combination of chemotherapeutic agents and embolization-induced local ischemia to produce antitumor effects, TARE uses microspheres containing radioisotopes that are small in volume (20-60 μm), and these delivery techniques do not cause notable arterial occlusion[62,75,76]. With further in-depth research on radioisotope delivery, it is expected that TARE will play a more important role in the treatment of HCC. Both TACE and TARE are promising methods for the treatment of patients with unresectable HCC; the combined use of TACE and TARE in one treatment course may produce a synergistic cytotoxic effect, thus improving the treatment effect. Recently, some scholars have focused on the combined application of chemotherapy and radioembolization agents in the same delivery system[77]. Alregib et al[77] recently developed a novel biodegradable microsphere formulation loaded with a chemotherapeutic drug (Dox) and radioactive agent (Sm-153) for potential radio-chemoembolization in advanced HCC. The study results showed that this formulation met all the needed physicochemical properties of the radio-chemoembolization agent and achieved better in vitro cytotoxicity against HepG2 cells. The biological safety, radiation dosimetry and synergistic anticancer properties of this agent need to be further evaluated in subsequent studies.
With continuous advancements in interventional radiology, important progress has been made in transarterial therapies for HCC in recent years. The recent 2022 update of the BCLC treatment algorithm features the prominent role of locoregional treatment in HCC, and transarterial therapies have established their place in the BCLC treatment algorithm. Currently, studies on the combination of local transarterial therapies with other treatments, including local ablation, radiation therapy, and systemic therapy, are actively being conducted; in particular, the combination of transarterial therapies with targeted therapy and immunotherapy is a new research hotspot. The rationale of this combination treatment strategy is that transarterial therapies may enhance the anticancer immune response and that TKIs have a synergistic effect with ICIs due to the antitumoral immunological effects of some targeted drugs such as sorafenib[78]. In addition, the optimal selection of patients is an extremely important issue to improve the efficacy of transarterial treatments. Granito et al[79] recently demonstrated that transient hypertransaminasemia after superselective cTACE was a simple and accurate marker for predicting the treatment response. However, more attention should be given to the prognostic score with consideration of liver function, as any treatment that severely compromises liver function will shorten life expectancy rather than prolong it[80]. New prognostic models, including the neutrophil-lymphocyte ratio, radiomics and deep learning, have been the focus of relevant researchers in recent years[81-87]. In the future, more studies are needed to determine the optimal transarterial local and combination treatment strategies for HCC[60,61,65,88,89]. With the emergence of checkpoint immunotherapy modalities, it is expected that the results of trials of transarterial local therapy combined with systemic therapy will bring new hope to HCC patients.
1. | Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43:13-25. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 224] [Cited by in F6Publishing: 275] [Article Influence: 45.8] [Reference Citation Analysis (0)] |
2. | Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301-1314. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2800] [Cited by in F6Publishing: 3621] [Article Influence: 603.5] [Reference Citation Analysis (3)] |
3. | Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2014;10:153-161. [PubMed] [Cited in This Article: ] |
4. | Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 109] [Cited by in F6Publishing: 149] [Article Influence: 37.3] [Reference Citation Analysis (0)] |
5. | Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 569] [Cited by in F6Publishing: 813] [Article Influence: 90.3] [Reference Citation Analysis (0)] |
6. | Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, Ravaioli M, D'Errico-Grigioni A, Pinna AD, Bolondi L. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011;53:1580-1589. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 188] [Cited by in F6Publishing: 206] [Article Influence: 15.8] [Reference Citation Analysis (0)] |
7. | Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28-36. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 180] [Cited by in F6Publishing: 344] [Article Influence: 57.3] [Reference Citation Analysis (0)] |
8. | Mondaca S, Yarmohammadi H, Kemeny NE. Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2019;28:717-729. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
9. | Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681-693. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1904] [Cited by in F6Publishing: 1714] [Article Influence: 857.0] [Reference Citation Analysis (58)] |
10. | He MK, Zou RH, Wei W, Shen JX, Zhao M, Zhang YF, Lin XJ, Zhang YJ, Guo RP, Shi M. Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. J Vasc Interv Radiol. 2018;29:1068-1077.e2. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
11. | Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1063] [Cited by in F6Publishing: 1138] [Article Influence: 75.9] [Reference Citation Analysis (0)] |
12. | Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426-432. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 310] [Cited by in F6Publishing: 371] [Article Influence: 30.9] [Reference Citation Analysis (0)] |
13. | Chen QW, Ying HF, Gao S, Shen YH, Meng ZQ, Chen H, Chen Z, Teng WJ. Radiofrequency ablation plus chemoembolization vs radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2016;40:309-314. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
14. | Huo YR, Eslick GD. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2015;1:756-765. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 117] [Cited by in F6Publishing: 155] [Article Influence: 19.4] [Reference Citation Analysis (0)] |
15. | Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim YS. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018;4:661-669. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 196] [Cited by in F6Publishing: 274] [Article Influence: 54.8] [Reference Citation Analysis (0)] |
16. | Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 2016;64:1090-1098. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 405] [Cited by in F6Publishing: 499] [Article Influence: 62.4] [Reference Citation Analysis (0)] |
17. | Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:565-575. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 309] [Cited by in F6Publishing: 338] [Article Influence: 48.3] [Reference Citation Analysis (0)] |
18. | Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69:1492-1501. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 221] [Cited by in F6Publishing: 406] [Article Influence: 101.5] [Reference Citation Analysis (0)] |
19. | Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab vs sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77-90. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 104] [Cited by in F6Publishing: 537] [Article Influence: 179.0] [Reference Citation Analysis (0)] |
20. | Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81-88. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 634] [Cited by in F6Publishing: 697] [Article Influence: 63.4] [Reference Citation Analysis (0)] |
21. | Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-873. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 309] [Cited by in F6Publishing: 624] [Article Influence: 312.0] [Reference Citation Analysis (0)] |
22. | Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab vs sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:995-1008. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 276] [Cited by in F6Publishing: 247] [Article Influence: 123.5] [Reference Citation Analysis (0)] |
23. | Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehí M, Miho M, Radu P, Dufour JF, Verslype C, Zimpel C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Finkelmeier F, Trojan J, Özdirik B, Müller T, Schmelzle M, Bejjani A, Sung MW, Schwartz ME, Finn RS, Thung S, Villanueva A, Sia D, Llovet JM. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology. 2023;164:72-88.e18. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 45] [Article Influence: 45.0] [Reference Citation Analysis (0)] |
24. | Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey JN, Venook AP, Yopp A, McMillian NR, Hochstetler C, Darlow SD. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:541-565. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 354] [Cited by in F6Publishing: 437] [Article Influence: 145.7] [Reference Citation Analysis (0)] |
25. | Qin J, Huang Y, Zhou H, Yi S. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis. Front Oncol. 2022;12:807102. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis (0)] |
26. | Sun T, Ren Y, Sun B, Chen L, Zhu L, Zhang L, Zheng C. The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC. J Hepatocell Carcinoma. 2023;10:447-457. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
27. | Hu Y, Pan T, Cai X, He QS, Zheng YB, Huang MS, Jiang ZB, Chen JW, Wu C. Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2023;14:1837-1848. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
28. | Zhang JX, Hua HJ, Cheng Y, Liu S, Shi HB, Zu QQ. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis. Acad Radiol. 2024;31:1304-1311. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Reference Citation Analysis (0)] |
29. | Yang XG, Sun YY, Wang HQ, Li DS, Xu GH, Huang XQ. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis. Front Oncol. 2022;12:914385. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
30. | Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci. 2020;7:609322. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 50] [Article Influence: 16.7] [Reference Citation Analysis (0)] |
31. | Jiang N, Zhong B, Huang J, Li W, Zhang S, Zhu X, Ni C, Shen J. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2023;14:1205636. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
32. | Dawood ZS, Brown ZJ, Alaimo L, Lima HA, Shaikh C, Katayama ES, Munir MM, Moazzam Z, Endo Y, Woldesenbet S, Pawlik TM. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis. HPB (Oxford). 2024;26:618-629. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
33. | Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Front Oncol. 2022;12:980214. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 7] [Reference Citation Analysis (0)] |
34. | Zou X, Xu Q, You R, Yin G. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. Cancer Med. 2023;12:11315-11333. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 4] [Reference Citation Analysis (0)] |
35. | Ma KP, Fu JX, Duan F, Wang MQ. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol. 2024;16:1236-1247. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (70)] |
36. | Duan R, Gong F, Wang Y, Huang C, Wu J, Hu L, Liu M, Qiu S, Lu L, Lin Y. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors vs TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2023;21:120. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 3] [Reference Citation Analysis (0)] |
37. | Long Y, Huang J, Liao J, Zhang D, Huang Z, He X, Zhang L. Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2023;15. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 1] [Reference Citation Analysis (0)] |
38. | Gao B, Yang F, Zheng D, Hu S, Liu J, Liu H, Liu Y, Liu L, Wang R, Zhao Y, Cui C, Fang C, Yang J, Su S, Han Y, Yang X, Li B. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. J Hepatocell Carcinoma. 2023;10:2265-2276. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 1] [Reference Citation Analysis (0)] |
39. | Feng J, Zhou J, Wu Y, Shen HM, Peng T, Lu GD. Targeting mitophagy as a novel therapeutic approach in liver cancer. Autophagy. 2023;19:2164-2165. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
40. | Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation vs symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2502] [Cited by in F6Publishing: 2526] [Article Influence: 114.8] [Reference Citation Analysis (0)] |
41. | Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer. 1994;74:2449-2453. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 3] [Reference Citation Analysis (0)] |
42. | Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992;31 Suppl:S1-S6. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 107] [Cited by in F6Publishing: 114] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
43. | Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108:1252-1259. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 93] [Cited by in F6Publishing: 108] [Article Influence: 9.8] [Reference Citation Analysis (0)] |
44. | Gao D, Xu X, Liu L, Zhang X, Liang X, Cen L, Liu Q, Yuan X, Yu Z. Combination of Peglated-H1/HGFK1 Nanoparticles and TAE in the Treatment of Hepatocellular Carcinoma. Appl Biochem Biotechnol. 2023;195:505-518. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
45. | Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol. 2022;40:150-160. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 151] [Article Influence: 50.3] [Reference Citation Analysis (0)] |
46. | Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154-2160. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 333] [Cited by in F6Publishing: 331] [Article Influence: 23.6] [Reference Citation Analysis (0)] |
47. | Li S, Xu J, Zhang H, Hong J, Si Y, Yang T, He Y, Ng DM, Zheng D. The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Chemotherapy. 2021;66:124-133. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
48. | Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588-595. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 241] [Cited by in F6Publishing: 248] [Article Influence: 11.3] [Reference Citation Analysis (0)] |
49. | Li SH, Mei J, Cheng Y, Li Q, Wang QX, Fang CK, Lei QC, Huang HK, Cao MR, Luo R, Deng JD, Jiang YC, Zhao RC, Lu LH, Zou JW, Deng M, Lin WP, Guan RG, Wen YH, Li JB, Zheng L, Guo ZX, Ling YH, Chen HW, Zhong C, Wei W, Guo RP. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. J Clin Oncol. 2023;41:1898-1908. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 31] [Reference Citation Analysis (0)] |
50. | Gourd K, Lai C, Reeves C. ESMO Virtual Congress 2020. Lancet Oncol. 2020;21:1403-1404. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
51. | He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M. Hepatic artery infusion chemotherapy using mFOLFOX vs transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer. 2017;36:83. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 75] [Article Influence: 10.7] [Reference Citation Analysis (0)] |
52. | Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9016] [Cited by in F6Publishing: 9734] [Article Influence: 608.4] [Reference Citation Analysis (1)] |
53. | Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3854] [Cited by in F6Publishing: 4422] [Article Influence: 276.4] [Reference Citation Analysis (0)] |
54. | Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3128] [Cited by in F6Publishing: 3273] [Article Influence: 545.5] [Reference Citation Analysis (0)] |
55. | He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5:953-960. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 142] [Cited by in F6Publishing: 283] [Article Influence: 70.8] [Reference Citation Analysis (0)] |
56. | Chen XL, Yu HC, Fan QG, Yuan Q, Jiang WK, Rui SZ, Zhou WC. Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis. Oncol Lett. 2022;24:366. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
57. | Li Z, Xu Y, Qu W, Liu P, Zhu Y, Li H, Guo Y, Liu X. Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and metaanalysis. Oncol Lett. 2023;26:534. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
58. | Zang M, Hu X, Yuan G, Li R, Li W, Pang H, Li Q, Chen J. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed vs oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study. Int Immunopharmacol. 2023;125:111019. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
59. | Tan Z, Zhang J, Xu L, Wang H, Mao X, Zou R, Wang Q, Han Z, Di Z, Wu D. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2023;18:e0290644. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
60. | Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Front Immunol. 2022;13:913464. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 17] [Reference Citation Analysis (0)] |
61. | Pan Y, Wang R, Hu D, Xie W, Fu Y, Hou J, Xu L, Zhang Y, Chen M, Zhou Z. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials. Front Biosci (Landmark Ed). 2021;26:873-881. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
62. | Briody H, Duong D, Yeoh SW, Hodgson R, Yong TL, Hannah A, Lee MJ, Leong S, Maingard J, Asadi H, Kok HK. Radioembolization for Treatment of Hepatocellular Carcinoma: Current Evidence and Patterns of Utilization. J Vasc Interv Radiol. 2023;34:1200-1213. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
63. | Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:1129-1145. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
64. | Yeo YH, Liang J, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, Sankar K, Gong J, Hendifar A, Osipov A, Friedman ML, Lipshutz HG, Steinberger J, Kosari K, Nissen N, Abou-Alfa GK, Singal AG, Yang JD. Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma. Am J Gastroenterol. 2023;118:2201-2211. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 1] [Reference Citation Analysis (0)] |
65. | Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A. Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers (Basel). 2022;15. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis (0)] |
66. | Saito A, Kitayama J, Nagai R, Aizawa K. Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review. Pharmaceutics. 2023;15. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 3] [Reference Citation Analysis (0)] |
67. | Zhao W, Xu J, You Y, Guo Z, Xiang Y, Hao K, He X, Zhao P. Thermoresponsive hydrogel for transcatheter arterial chemoembolization of hepatocellular carcinoma. Chem Commun (Camb). 2023;59:9352-9355. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
68. | Bzeizi KI, Arabi M, Jamshidi N, Albenmousa A, Sanai FM, Al-Hamoudi W, Alghamdi S, Broering D, Alqahtani SA. Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021;13. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis (0)] |
69. | Nouri YM, Kim JH, Yoon HK, Ko HK, Shin JH, Gwon DI. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol. 2019;20:34-49. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 34] [Cited by in F6Publishing: 52] [Article Influence: 8.7] [Reference Citation Analysis (0)] |
70. | Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330-1335. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 331] [Cited by in F6Publishing: 357] [Article Influence: 29.8] [Reference Citation Analysis (0)] |
71. | Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26:516-522. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis (0)] |
72. | Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol. 2013;36:706-713. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 87] [Cited by in F6Publishing: 93] [Article Influence: 7.8] [Reference Citation Analysis (0)] |
73. | Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Kakizaki S, Sato K. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol Res. 2015;45:663-666. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis (0)] |
74. | Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2018;10:485-495. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis (1)] |
75. | Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021;74:2342-2352. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 100] [Cited by in F6Publishing: 233] [Article Influence: 77.7] [Reference Citation Analysis (0)] |
76. | Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology. 2013;58:2188-2197. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 125] [Cited by in F6Publishing: 135] [Article Influence: 12.3] [Reference Citation Analysis (0)] |
77. | Alregib AH, Tan HY, Wong YH, Kasbollah A, Wong EH, Abdullah BJJ, Perkins AC, Yeong CH. Development and physicochemical characterization of a biodegradable microspheres formulation loaded with samarium-153 and doxorubicin for chemo-radioembolization of liver tumours. J Labelled Comp Radiopharm. 2023;66:308-320. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
78. | Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F, Granito A. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23:279-291. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 49] [Reference Citation Analysis (0)] |
79. | Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, Cappelli A, Antonino M, Modestino F, Brandi N, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J Pers Med. 2021;11. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 49] [Article Influence: 16.3] [Reference Citation Analysis (0)] |
80. | D'Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76:1185-1198. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis (0)] |
81. | Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Int. 2019;39:1704-1712. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 41] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis (0)] |
82. | Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G; China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 97] [Cited by in F6Publishing: 137] [Article Influence: 27.4] [Reference Citation Analysis (0)] |
83. | Chon YE, Park H, Hyun HK, Ha Y, Kim MN, Kim BK, Lee JH, Kim SU, Kim DY, Ahn SH, Hwang SG, Han KH, Rim KS, Park JY. Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers (Basel). 2019;11. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis (0)] |
84. | Sun Y, Bai H, Xia W, Wang D, Zhou B, Zhao X, Yang G, Xu L, Zhang W, Liu P, Xu J, Meng S, Liu R, Gao X. Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI. J Magn Reson Imaging. 2020;52:1083-1090. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
85. | Blanc-Durand P, Van Der Gucht A, Jreige M, Nicod-Lalonde M, Silva-Monteiro M, Prior JO, Denys A, Depeursinge A, Schaefer N. Signature of survival: a (18)F-FDG PET based whole-liver radiomic analysis predicts survival after (90)Y-TARE for hepatocellular carcinoma. Oncotarget. 2018;9:4549-4558. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
86. | Mao Q, Zhou MT, Zhao ZP, Liu N, Yang L, Zhang XM. Role of radiomics in the diagnosis and treatment of gastrointestinal cancer. World J Gastroenterol. 2022;28:6002-6016. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis (64)] |
87. | Gong XQ, Liu N, Tao YY, Li L, Li ZM, Yang L, Zhang XM. Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma. Sci Rep. 2023;13:7710. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
88. | Himmelsbach V, Koch C, Trojan J, Finkelmeier F. Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions? J Hepatocell Carcinoma. 2024;11:363-372. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
89. | Kirstein MM, Wirth TC. [Multimodal treatment of hepatocellular carcinoma]. Internist (Berl). 2020;61:164-169. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis (0)] |